FDA approves Novartis drug to treat pancreatic neuroendocrine tumors

Friday, May 6, 2011 12:34 PM

The FDA has approved the Novartis drug Afinitor(everolimus) for the treatment of advanced pancreatic neuroendocrine tumors. 

Afinitor underwent rigorous clinical trials to determine the safety and effectiveness of the drug in this specific cancer type.  It was previously approved to treat other cancer types, but needed to prove efficacy in patients with pancreatic neuroendocrine tumors.  Afinitor is designed to attack specific proteins that are necessary for the growth of cancer cells.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs